{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:38:06Z","timestamp":1795081086028,"version":"4.10.2"},"reference-count":203,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.eururo.2025.02.023","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T05:14:24Z","timestamp":1742447664000},"page":"697-716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":171,"title":["European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update"],"prefix":"10.1016","volume":"87","author":[{"given":"Alexandra","family":"Masson-Lecomte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otakar","family":"Capoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Dom\u00ednguez-Escrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Makaroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramananthan","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavan P.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Y.C.","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos N.","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.02.023_b0005","series-title":"EAU guidelines on non-muscle-invasive bladder cancer (T1, T1 and CIS)","author":"Gontero","year":"2025"},{"key":"10.1016\/j.eururo.2025.02.023_b0010","series-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer","author":"van der Heijden","year":"2025"},{"key":"10.1016\/j.eururo.2025.02.023_b0015","series-title":"EAU guidelines on primary urethral carcinoma","author":"Neuzillet","year":"2025"},{"key":"10.1016\/j.eururo.2025.02.023_b0020","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2025.02.023_b0025","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2025.02.023_b0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-010-0594-7","article-title":"Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma","volume":"29","author":"Shariat","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0035","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.02.023_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2018.01.015","article-title":"An analysis of staging and treatment trends for upper tract urothelial carcinoma in the National Cancer Database","volume":"16","author":"Browne","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.02.023_b0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00345-012-0877-2","article-title":"Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma","volume":"31","author":"Cosentino","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0050","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.juro.2016.11.094","article-title":"A multi-institutional comparison of clinicopathological characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States","volume":"197","author":"Singla","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0055","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.1998.16.3.1099","article-title":"Extravesical tumor relapse in patients with superficial bladder tumors","volume":"16","author":"Herr","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0090-4295(93)90329-9","article-title":"Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG","volume":"42","author":"Miller","year":"1993","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.02.023_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.02.009","article-title":"Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guerin therapy for nonmuscle-invasive bladder cancer: results from a multi-institutional retrospective study","volume":"36","author":"Nishiyama","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1464-410X.2007.06841.x","article-title":"Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments","volume":"100","author":"Sanderson","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0075","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.eururo.2014.11.035","article-title":"A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma","volume":"67","author":"Seisen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0080","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.eururo.2009.12.032","article-title":"Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma","volume":"57","author":"Li","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0085","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0090","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1464-410X.2009.08838.x","article-title":"Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract","volume":"104","author":"Colin","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0095","series-title":"Upper tract urothelial carcinoma","article-title":"Epidemiology and risk factors for upper urinary urothelial cancers","author":"Dickman","year":"2015"},{"key":"10.1016\/j.eururo.2025.02.023_b0100","first-page":"254","article-title":"Cigarette smoking and cancers of the renal pelvis and ureter","volume":"52","author":"McLaughlin","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2025.02.023_b0105","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2013.06.010","article-title":"Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature","volume":"65","author":"Crivelli","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/em.21756","article-title":"Aristolochic acid nephropathy: harbinger of a global iatrogenic disease","volume":"54","author":"Grollman","year":"2013","journal-title":"Environ Mol Mutagen"},{"key":"10.1016\/j.eururo.2025.02.023_b0115","first-page":"45","article-title":"Aristolochic acids","volume":"12","author":"National Toxicology Program","year":"2011","journal-title":"Rep Carcinog"},{"key":"10.1016\/j.eururo.2025.02.023_b0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200326010-00004","article-title":"Aristolochic acid and \u2018Chinese herbs nephropathy\u2019: a review of the evidence to date","volume":"26","author":"Cosyns","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.eururo.2025.02.023_b0125","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1470-2045(09)70041-5","article-title":"Management of extracolonic tumours in patients with Lynch syndrome","volume":"10","author":"Koornstra","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0130","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/PAS.0000000000001141","article-title":"Universal Lynch syndrome screening should be performed in all upper tract urothelial carcinomas","volume":"42","author":"Ju","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2025.02.023_b0135","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/1878-0261.12325","article-title":"Molecular subtype classification of urothelial carcinoma in Lynch syndrome","volume":"12","author":"Therkildsen","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0140","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0016-5085(99)70510-X","article-title":"New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC","volume":"116","author":"Vasen","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eururo.2025.02.023_b0145","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1136\/jmg.2003.017871","article-title":"Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma","volume":"41","author":"Roupret","year":"2004","journal-title":"J Med Genet"},{"key":"10.1016\/j.eururo.2025.02.023_b0150","doi-asserted-by":"crossref","DOI":"10.1111\/j.1464-410X.2012.11298.x","article-title":"A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool","volume":"110","author":"Audenet","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0155","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.eururo.2008.08.008","article-title":"Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum","volume":"54","author":"Roupret","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0160","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1464-410X.2010.09443.x","article-title":"Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma","volume":"106","author":"Acher","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0165","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bju.16405","article-title":"A collaborative review of the microsatellite instability\/deficient mismatch repair phenotype in patients with upper tract urothelial carcinoma","volume":"134","author":"Gabriel","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0170","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/ajcp\/aqaa100","article-title":"Universal mismatch repair protein screening in upper tract urothelial carcinoma","volume":"154","author":"Gayhart","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.eururo.2025.02.023_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2020.03.006","article-title":"Loss of mismatch-repair protein expression and microsatellite instability in upper tract urothelial carcinoma and clinicopathologic implications","volume":"18","author":"Schneider","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.02.023_b0180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jjco\/hyz140","article-title":"Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population","volume":"50","author":"Ito","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.urology.2022.02.006","article-title":"Immunohistochemical screening of upper tract urothelial carcinomas for Lynch syndrome diagnostics: a systematic review","volume":"165","author":"Rasmussen","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.02.023_b0190","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s10147-014-0721-3","article-title":"Impact of variant histology on disease aggressiveness and outcome after nephroureterectomy in Japanese patients with upper tract urothelial carcinoma","volume":"20","author":"Sakano","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0195","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ctrv.2010.12.005","article-title":"Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature","volume":"37","author":"Ouzzane","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2025.02.023_b0200","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.juro.2012.04.009","article-title":"Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma","volume":"188","author":"Rink","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0205","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/JU.0000000000000523","article-title":"Prognostic value of variant histology in upper tract urothelial carcinoma treated with nephroureterectomy: a systematic review and meta-analysis","volume":"203","author":"Mori","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0210","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/bju.14751","article-title":"Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy","volume":"124","author":"Zamboni","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.02.010","article-title":"Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma","volume":"35","author":"Kim","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0220","doi-asserted-by":"crossref","first-page":"30988","DOI":"10.1038\/srep30988","article-title":"Unique transcriptomic profile of collecting duct carcinomas relative to upper tract urothelial carcinomas and other kidney carcinomas","volume":"6","author":"Malouf","year":"2016","journal-title":"Sci Rep."},{"key":"10.1016\/j.eururo.2025.02.023_b0225","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.eururo.2020.05.039","article-title":"Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature","volume":"78","author":"Hassler","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0230","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0235","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.ejso.2020.06.024","article-title":"Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: systematic review and meta-analysis","volume":"46","author":"Subiela","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0240","series-title":"TNM classification of malignant tumours","year":"2016"},{"key":"10.1016\/j.eururo.2025.02.023_b0245","series-title":"WHO classification of tumours of the urinary system and male genital organs","article-title":"Tumours of the urinary system: non-invasive urothelial neoplasias","author":"Sauter","year":"2004"},{"key":"10.1016\/j.eururo.2025.02.023_b0250","series-title":"WHO classification of tumours of the urinary system and male genital organs","year":"2016"},{"key":"10.1016\/j.eururo.2025.02.023_b0255","series-title":"WHO classification of tumours. Urinary and male genital tumours","author":"WHO Classification of Tumours Editorial Board","year":"2022"},{"key":"10.1016\/j.eururo.2025.02.023_b0260","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MOU.0000000000000899","article-title":"Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry","volume":"31","author":"Baard","year":"2021","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0265","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.urolonc.2009.11.007","article-title":"Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?","volume":"29","author":"Raman","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0270","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1464-410X.2007.06766.x","article-title":"Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour","volume":"99","author":"Cowan","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0275","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00345-019-02875-8","article-title":"Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis","volume":"38","author":"Janisch","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0280","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00345-011-0710-3","article-title":"Predictive factors of recurrence and survival of upper tract urothelial carcinomas","volume":"29","author":"Verhoest","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0285","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/JU.0000000000003085","article-title":"Diagnostic accuracy of clinical lymph node staging for upper tract urothelial cancer patients: a multicenter, retrospective, observational study","volume":"209","author":"Pallauf","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0290","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.juro.2009.12.031","article-title":"Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy","volume":"183","author":"Takahashi","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0295","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.euo.2019.09.004","article-title":"Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma","volume":"3","author":"Voskuilen","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0300","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0305","series-title":"The Paris system for reporting urinary cytology","year":"2022"},{"key":"10.1016\/j.eururo.2025.02.023_b0310","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1464-410X.2010.09899.x","article-title":"Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma","volume":"108","author":"Messer","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0315","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/21681805.2017.1295102","article-title":"Diagnostic accuracy of upper tract urothelial carcinoma: how samples are collected matters","volume":"51","author":"Malm","year":"2017","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0320","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.3390\/cancers14061520","article-title":"Non-invasive biomarkers in the diagnosis of upper urinary tract urothelial carcinoma\u2014a systematic review","volume":"14","author":"Bialek","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2025.02.023_b0325","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.urolonc.2012.05.010","article-title":"Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma","volume":"31","author":"Rojas","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2021.10.002","article-title":"Discordance between clinical and pathological staging and grading in upper tract urothelial carcinoma","volume":"20","author":"Mori","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.02.023_b0335","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.urology.2011.02.038","article-title":"Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management","volume":"78","author":"Smith","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.02.023_b0340","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1089\/end.2011.0426","article-title":"High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection","volume":"26","author":"Clements","year":"2012","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2025.02.023_b0345","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.juro.2010.03.030","article-title":"Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma","volume":"184","author":"Brien","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0350","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000001834","article-title":"The impact of upper tract urothelial carcinoma diagnostic modality on intravesical recurrence after radical nephroureterectomy: a single institution series and updated meta-analysis","volume":"206","author":"Sharma","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0355","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.3390\/jcm10184197","article-title":"The impact of diagnostic ureteroscopy prior to radical nephroureterectomy on oncological outcomes in patients with upper tract urothelial carcinoma: a comprehensive systematic review and meta-analysis","volume":"10","author":"Nowak","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.eururo.2025.02.023_b0360","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/end.2014.0551","article-title":"Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications","volume":"29","author":"Bus","year":"2015","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2025.02.023_b0365","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdw170","article-title":"Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment","volume":"27","author":"Pouessel","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0370","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.023_b0375","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.euo.2020.11.005","article-title":"Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma","volume":"4","author":"Colla Ruvolo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0380","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/bju.15389","article-title":"Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017","volume":"128","author":"van Doeveren","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0385","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/jso.25877","article-title":"Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract","volume":"121","author":"Rosiello","year":"2020","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0390","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.eururo.2009.07.002","article-title":"Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy","volume":"57","author":"Raman","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0395","doi-asserted-by":"crossref","first-page":"377","DOI":"10.21037\/atm.2019.07.31","article-title":"Impact of squamous differentiation on intravesical recurrence and prognosis of patients with upper tract urothelial carcinoma","volume":"7","author":"Yu","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.eururo.2025.02.023_b0400","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/modpathol.3800559","article-title":"High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants","volume":"19","author":"Perez-Montiel","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2025.02.023_b0405","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S0022-5347(17)38150-8","article-title":"Computerized tomography for detection and staging of localized and pathologically defined upper tract urothelial tumors","volume":"146","author":"McCoy","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0410","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/21681805.2021.1877343","article-title":"Preoperative predictors of pathological tumour stage and prognosis may be used when selecting candidates for intensified treatment in upper tract urothelial carcinoma","volume":"55","author":"Almas","year":"2021","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0415","doi-asserted-by":"crossref","DOI":"10.1111\/j.1464-410X.2011.10792.x","article-title":"Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy","volume":"110","author":"Yafi","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0420","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.eururo.2011.09.017","article-title":"The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy","volume":"61","author":"Chromecki","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0425","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.urolonc.2014.04.006","article-title":"Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration","volume":"32","author":"Fradet","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0430","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.eururo.2010.07.003","article-title":"The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center","volume":"58","author":"Favaretto","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0435","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.600511","article-title":"Prognostic value of preoperative hydronephrosis in patients undergoing radical nephroureterectomy for upper tract urinary carcinoma: a systematic review and meta-analysis","volume":"10","author":"Ye","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0440","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.euros.2022.06.001","article-title":"Prognostic value of tumor size in patients with upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"42","author":"Ma","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2025.02.023_b0445","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.euf.2021.03.003","article-title":"Tumor size predicts muscle-invasive and non-organ-confined disease in upper tract urothelial carcinoma at radical nephroureterectomy","volume":"8","author":"Colla Ruvolo","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.023_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2020.09.002","article-title":"The performance of tumor size as risk stratification parameter in upper tract urothelial carcinoma (UTUC)","volume":"19","author":"Foerster","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.02.023_b0455","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s12253-019-00748-4","article-title":"Development and validation of a model for predicting intravesical recurrence in organ-confined upper urinary tract urothelial carcinoma patients after radical nephroureterectomy: a retrospective study in one center with long-term follow-up","volume":"26","author":"Zhang","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.eururo.2025.02.023_b0460","doi-asserted-by":"crossref","first-page":"19059","DOI":"10.1038\/s41598-021-98696-0","article-title":"Tumor distribution affects bladder recurrence but not survival outcome of multifocal upper tract urothelial carcinoma treated with radical nephroureterectomy","volume":"11","author":"Sheu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2025.02.023_b0465","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bju.13935","article-title":"Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis","volume":"120","author":"Marchioni","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0470","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bju.14053","article-title":"Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis","volume":"121","author":"Guo","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281304","article-title":"Preoperative upper tract invasive diagnostic modalities are associated with intravesical recurrence following surgery for upper tract urothelial carcinoma: a population-based study","volume":"18","author":"Liedberg","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2025.02.023_b0480","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00345-023-04734-z","article-title":"Focused UTUC pathways with a risk-stratified approach to diagnostic ureteroscopy: is it the need of the hour? A retrospective cohort analysis","volume":"42","author":"Parmar","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0485","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Non\u2013muscle Invasive Bladder Cancer Guidelines Panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2023.09.019","article-title":"Oncologic outcomes of patients treated with kidney-sparing surgery or radical nephroureterectomy for upper urinary tract urothelial cancer: a population-based study","volume":"42","author":"Slusarczyk","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0495","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1111\/j.1464-410X.2012.11169.x","article-title":"Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience","volume":"110","author":"Cutress","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0500","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","article-title":"Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review","volume":"110","author":"Cutress","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0505","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00345-009-0494-x","article-title":"Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma","volume":"28","author":"Cornu","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0510","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00345-015-1753-7","article-title":"Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings","volume":"34","author":"Villa","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0515","first-page":"115","article-title":"Survival comparison between endoscopic and surgical management for patients with upper tract urothelial cancer: a matched propensity score analysis using Surveillance","volume":"95","author":"Vemana","year":"2016","journal-title":"Epidemiology and End Results-Medicare data. Urology"},{"key":"10.1016\/j.eururo.2025.02.023_b0520","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.euf.2022.11.016","article-title":"Oncologic and safety outcomes for endoscopic surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: an updated systematic review and meta-analysis","volume":"9","author":"Kawada","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.023_b0525","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00345-023-04577-8","article-title":"The importance of second-look ureteroscopy implementation in the conservative management of upper tract urothelial carcinoma","volume":"41","author":"Gallioli","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0530","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2006.07.019","article-title":"Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection","volume":"51","author":"Roupret","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0535","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1464-410X.2007.06753.x","article-title":"Partial nephrectomy and autotransplantation with pyelovesicostomy for renal urothelial carcinoma in solitary kidneys: a clinical update","volume":"99","author":"Steffens","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0540","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12894-018-0389-5","article-title":"Long-term outcomes of total ureterectomy with ileal-ureteral substitution treatment for ureteral cancer: a single-center experience","volume":"18","author":"Ou","year":"2018","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0545","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1464-410X.2012.10960.x","article-title":"Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study","volume":"110","author":"Colin","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0550","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.clgc.2022.01.007","article-title":"Segmental ureterectomy versus radical nephroureterectomy in older patients treated for upper tract urothelial carcinoma","volume":"20","author":"Abrate","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.02.023_b0555","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.juro.2011.09.150","article-title":"Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma","volume":"187","author":"Silberstein","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0560","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.juro.2016.03.194","article-title":"Upper urinary tract carcinoma in situ: current knowledge, future direction","volume":"197","author":"Redrow","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0565","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.eururo.2011.07.051","article-title":"Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit?","volume":"60","author":"Giannarini","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0570","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0090-4295(01)01488-1","article-title":"Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter","volume":"59","author":"Irie","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.02.023_b0575","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12032-018-1102-y","article-title":"Impact of bacillus Calmette-Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy","volume":"35","author":"Horiguchi","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0580","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/07357907.2018.1430815","article-title":"Efficacy and tolerability of bacillus Calmette-Guerin therapy as the first-line therapy for upper urinary tract carcinoma in situ","volume":"36","author":"Tomisaki","year":"2018","journal-title":"Cancer Investig"},{"key":"10.1016\/j.eururo.2025.02.023_b0585","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/01.ju.0000147747.89028.64","article-title":"Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation","volume":"173","author":"Yossepowitch","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0590","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/end.2019.0750","article-title":"Adjuvant single-dose upper urinary tract instillation of mitomycin C After therapeutic ureteroscopy for upper tract urothelial carcinoma: a single-centre prospective non-randomized trial","volume":"34","author":"Gallioli","year":"2020","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2025.02.023_b0595","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1089\/end.2021.0587","article-title":"Robotic vs laparoscopic nephroureterectomy for upper tract urothelial carcinoma: a multicenter propensity-score matched pair \u201ctetrafecta\u201d analysis (ROBUUST collaborative group)","volume":"36","author":"Veccia","year":"2022","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2025.02.023_b0600","article-title":"Robot-assisted vs. laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis based on comparative studies. Front","volume":"12","author":"Ji","year":"2022","journal-title":"Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0605","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/bco2.208","article-title":"Robotic-assisted versus laparoscopic nephroureterectomy; a systematic review and meta-analysis","volume":"4","author":"O\u2019Sullivan","year":"2023","journal-title":"BJUI Compass"},{"key":"10.1016\/j.eururo.2025.02.023_b0610","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.eururo.2011.12.026","article-title":"Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series","volume":"61","author":"Hanna","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0615","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.euf.2017.10.003","article-title":"Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an European Association of Urology guidelines systematic review","volume":"5","author":"Peyronnet","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.023_b0620","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.eururo.2010.08.005","article-title":"Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?","volume":"58","author":"Favaretto","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0625","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1464-410X.2010.09826.x","article-title":"Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort","volume":"108","author":"Walton","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0630","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.eururo.2012.02.019","article-title":"Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies","volume":"61","author":"Ni","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0635","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1245\/s10434-011-1841-x","article-title":"Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study","volume":"19","author":"Ariane","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0640","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.3390\/cancers15204926","article-title":"Oncological efficacy of robotic nephroureterectomy vs. open and laparoscopic nephroureterectomy for suspected non-metastatic UTUC\u2014a systematic review and meta-analysis","volume":"15","author":"Rajan","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2025.02.023_b0645","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2009.06.013","article-title":"Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study","volume":"56","author":"Simone","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0650","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00345-008-0349-x","article-title":"Oncological risk of laparoscopic surgery in urothelial carcinomas","volume":"27","author":"Roupret","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0655","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/01.ju.0000084660.73614.da","article-title":"Trocar site recurrence after laparoscopic nephroureterectomy","volume":"170","author":"Ong","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0660","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.juro.2009.12.018","article-title":"Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter","volume":"183","author":"Jeldres","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0665","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.eururo.2012.04.052","article-title":"Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma","volume":"65","author":"Xylinas","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0670","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2013.09.003","article-title":"Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool","volume":"65","author":"Xylinas","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0675","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1464-410X.2010.09835.x","article-title":"Does the surgical technique for management of the distal ureter influence the outcome after nephroureterectomy?","volume":"108","author":"Phe","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0680","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.euf.2017.09.015","article-title":"Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the European Association of Urology Guidelines Panel on Non\u2013muscle-invasive Bladder Cancer","volume":"5","author":"Dominguez-Escrig","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.023_b0685","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.urology.2009.07.1296","article-title":"A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma","volume":"75","author":"Lughezzani","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.02.023_b0690","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00345-017-2026-4","article-title":"Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy","volume":"35","author":"Moschini","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0695","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.juro.2012.09.036","article-title":"Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy","volume":"189","author":"Xylinas","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0700","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.euros.2023.09.010","article-title":"Location of retroperitoneal lymph node metastases in upper tract urothelial carcinoma: results from a prospective lymph node mapping study","volume":"57","author":"Bobjer","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2025.02.023_b0705","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.juro.2015.06.077","article-title":"Patterns of lymphatic metastases in upper tract urothelial carcinoma and proposed dissection templates","volume":"194","author":"Matin","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0710","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/iju.12338","article-title":"Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: a prospective study","volume":"21","author":"Kondo","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0715","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1442-2042.2010.02610.x","article-title":"Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival","volume":"17","author":"Kondo","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0720","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.3390\/cancers14215452","article-title":"Oncological outcomes of distal ureterectomy for high-risk urothelial carcinoma: a multicenter study by the French Bladder Cancer Committee","volume":"14","author":"Masson-Lecomte","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2025.02.023_b0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2023.04.013","article-title":"The impact of routine frozen section analysis during nephroureterectomy or segmental ureterectomy for urothelial carcinoma on final surgical margin status and long-term oncologic outcome","volume":"41","author":"Lima","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0730","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.juro.2017.07.088","article-title":"Which patients with upper tract urothelial carcinoma can be safely treated with flexible ureteroscopy with holmium:YAG laser photoablation? Long-term results from a high volume institution","volume":"199","author":"Villa","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0735","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1089\/end.2023.0092","article-title":"Long-term oncologic outcomes of endoscopic management of high-risk upper tract urothelial carcinoma: the Fundacio Puigvert\u2019s experience","volume":"37","author":"Baboudjian","year":"2023","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2025.02.023_b0740","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000000644","article-title":"Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma","volume":"203","author":"Margulis","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0745","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.22.00763","article-title":"Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma","volume":"41","author":"Coleman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0750","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.05.014","article-title":"A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02","volume":"40","author":"Necchi","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0760","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrurol.2015.24","article-title":"Risk-adapted strategy for the kidney-sparing management of upper tract tumours","volume":"12","author":"Seisen","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0765","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2011.05.064","article-title":"Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C trial)","volume":"60","author":"O\u2019Brien","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0770","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2012.45.2128","article-title":"Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group trial","volume":"31","author":"Ito","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0775","article-title":"Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma","volume":"2019","author":"Hwang","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2025.02.023_b0780","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000350508","article-title":"Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis","volume":"91","author":"Fang","year":"2013","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2025.02.023_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2019.07.019","article-title":"Single versus maintenance intravesical chemotherapy for the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a randomized clinical trial","volume":"17","author":"Harraz","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.02.023_b0790","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.23.01659","article-title":"Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: final results of the POUT trial","volume":"42","author":"Birtle","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0795","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00345-019-03003-2","article-title":"Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis","volume":"38","author":"Tully","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0800","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.023_b0805","unstructured":"European Medicines Agency. European Commission approval for Opdivo (nivolumab) as adjuvant treatment for patients with radically resected, high-risk muscle-invasive urothelial carcinoma with tumor cell PD-L1 expression \u22651%. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf."},{"key":"10.1016\/j.eururo.2025.02.023_b0810","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.023_b0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103570","article-title":"Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes","volume":"169","author":"Laukhtina","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2025.02.023_b0820","first-page":"4051","article-title":"Effect of adjuvant radiotherapy on survival in patients with locoregional urothelial malignancies of the upper urinary tract","volume":"36","author":"Hahn","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2025.02.023_b0825","doi-asserted-by":"crossref","first-page":"38175","DOI":"10.1038\/srep38175","article-title":"Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma","volume":"6","author":"Huang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2025.02.023_b0830","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/01.ju.0000137910.38441.8a","article-title":"Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter","volume":"172","author":"Czito","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0835","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.urolonc.2019.05.021","article-title":"The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: a systematic review","volume":"37","author":"Iwata","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2022.04.015","article-title":"Benefit of lymph node dissection in cN+ patients in the treatment of upper tract urothelial carcinoma: analysis of NCDB registry","volume":"40","author":"Piontkowski","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.07.029","article-title":"Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study","volume":"40","author":"Shigeta","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0850","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/JU.0000000000000172","article-title":"Optimizing the sequence of chemotherapy for upper tract urothelial carcinoma with clinically positive regional lymph nodes","volume":"202","author":"Chakiryan","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0855","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.023_b0860","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.juro.2017.11.068","article-title":"Impact of primary tumor location on survival from the European Organization for the Research and Treatment of Cancer advanced urothelial cancer studies","volume":"199","author":"Moschini","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0865","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.023_b0870","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0875","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"18 Suppl","key":"10.1016\/j.eururo.2025.02.023_b0880","article-title":"Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis","volume":"38","author":"Powles","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0885","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0890","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.02.023_b0895","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.023_b0900","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.023_b0905","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/genes12030333","article-title":"Current knowledge on genomic profiling of upper tract urothelial carcinoma","volume":"12","author":"De Lorenzis","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.eururo.2025.02.023_b0910","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0915","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.023_b0920","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.eururo.2016.11.012","article-title":"Efficacy of systemic chemotherapy plus radical nephroureterectomy for metastatic upper tract urothelial carcinoma","volume":"71","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0925","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.euo.2019.06.014","article-title":"Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter, multidisciplinary database","volume":"3","author":"Moschini","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0930","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.1002\/cam4.4327","article-title":"The role of surgery on primary site in metastatic upper urinary tract urothelial carcinoma and a nomogram for predicting the survival of patients with metastatic upper urinary tract urothelial carcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.eururo.2025.02.023_b0935","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10585-018-9884-z","article-title":"How do organ-specific metastases affect prognosis and surgical treatment for patients with metastatic upper tract urothelial carcinoma: first evidence from population based data","volume":"34","author":"Dong","year":"2017","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.eururo.2025.02.023_b0940","article-title":"Survival effect of nephroureterectomy in metastatic upper urinary tract urothelial carcinoma","volume":"17","author":"Nazzani","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.02.023_b0945","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s11255-011-9915-z","article-title":"Prognostic factors for upper urinary tract urothelial carcinomas: stage, grade, and smoking status","volume":"43","author":"Simsir","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2025.02.023_b0950","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ju.0000099823.60465.e6","article-title":"Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience","volume":"171","author":"Siefker-Radtke","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0955","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.eururo.2007.02.052","article-title":"Impact of multimodal treatment on survival in patients with metastatic urothelial cancer","volume":"52","author":"Abe","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.09.009","article-title":"Metastasectomy in older adults with urothelial carcinoma: population-based analysis of use and outcomes","volume":"36","author":"Faltas","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.023_b0965","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.eururo.2012.02.042","article-title":"Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence","volume":"61","author":"Xylinas","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0970","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.juro.2017.06.073","article-title":"The conditional survival with time of intravesical recurrence of upper tract urothelial carcinoma","volume":"198","author":"Shigeta","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0975","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/JU.0000000000002748","article-title":"DNA methylation urine biomarkers test in the diagnosis of upper tract urothelial carcinoma: results from a single-center prospective clinical trial","volume":"208","author":"Territo","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b0980","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cncy.22343","article-title":"A review of upper urinary tract cytology performance before and after the implementation of the Paris system","volume":"129","author":"Zhang","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.eururo.2025.02.023_b0985","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/DCR.0000000000002062","article-title":"Evaluation of urinalysis-based screening for urothelial carcinoma in patients with Lynch syndrome","volume":"65","author":"Chouhan","year":"2022","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.eururo.2025.02.023_b0990","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10689-008-9193-9","article-title":"Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer","volume":"7","author":"Myrhoj","year":"2008","journal-title":"Fam Cancer"},{"key":"10.1016\/j.eururo.2025.02.023_b0995","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2020.03.043","article-title":"Propensity for quality: no longer a tenuous proposition in bladder cancer","volume":"78","author":"Mariappan","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b1000","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/MOU.0000000000000895","article-title":"Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy","volume":"31","author":"Konig","year":"2021","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2025.02.023_b1005","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3390\/cancers14071781","article-title":"Pentafecta for radical nephroureterectomy in patients with high-risk upper tract urothelial carcinoma: a proposal for standardization of quality care metrics","volume":"14","author":"Konig","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2025.02.023_b1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2022.05.010","article-title":"Radical nephroureterectomy tetrafecta: a proposal reporting surgical strategy quality at surgery","volume":"42","author":"Soria","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2025.02.023_b1015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.urology.2020.07.062","article-title":"The impact of hospital volume on short-term and long-term outcomes for patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma","volume":"147","author":"Sui","year":"2021","journal-title":"Urology"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T20:30:56Z","timestamp":1762288256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825001459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":203,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0302283825001459"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.02.023","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}